PubMed COVID-19 Clinical Care

Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5

Monday, January 22, 2024 - 4:00 AM

The receptor-binding domain (RBD) of the SARS-CoV-2 spike is a primary target of neutralizing antibodies and a key component of licensed vaccines. Substantial mutations in RBD, however, enable current variants to escape immunogenicity generated by

Endemic Human Coronavirus-Specific Nasal Immunoglobulin A and Serum Immunoglobulin G Dynamics in Lower Respiratory Tract Infections

Monday, January 22, 2024 - 4:00 AM

Endemic human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 cause respiratory infection. Following infection, a virus-specific serum antibody rise is usually observed, coinciding with recovery. In some cases, an infection is not accompanied by an

Erratum for Sazed et al., "Direct Nasal Swab for Rapid Test and Saliva as an Alternative Biological Sample for RT-PCR in COVID-19 Diagnosis"

Monday, January 22, 2024 - 4:00 AM

No abstract

Exploring Perceptions and Practices Regarding Adult Vaccination against Seasonal Influenza, Tetanus, Pneumococcal Disease, Herpes Zoster and COVID-19: A Mixed-Methods Study in Greece

Monday, January 22, 2024 - 4:00 AM

We aimed to document vaccination coverage for five vaccines, predictors of each vaccine's uptake and attitudes regarding adult vaccination. Adults visiting four pharmacies were randomly invited to participate during summer 2022. Among 395

Early prediction of sepsis in intensive care patients using the machine learning algorithm NAVOY® Sepsis, a prospective randomized clinical validation study

Saturday, January 20, 2024 - 4:00 AM

CONCLUSIONS: The accuracy, sensitivity, and specificity were all high, validating the prognostic accuracy of NAVOY® Sepsis in an ICU setting, including Covid-19 patients.

Effect of chemical and physical agents on monkeypox virus infectivity and downstream research applications

Saturday, January 20, 2024 - 4:00 AM

The 2022 global spread of Monkeypox Virus (MPXV) underlined the need to investigate safe-handling procedures of clinical and research samples. Here we evaluated the efficiency in reducing MPXV infectious titer of Triton X-100 (0.1 and 0.2%), UV-C

Explainable artificial intelligence approaches for COVID-19 prognosis prediction using clinical markers

Saturday, January 20, 2024 - 4:00 AM

The COVID-19 influenza emerged and proved to be fatal, causing millions of deaths worldwide. Vaccines were eventually discovered, effectively preventing the severe symptoms caused by the disease. However, some of the population (elderly and patients

Extracardiac findings with increased perfusion during clinical O-15-H2O PET/CT myocardial perfusion imaging: A case series

Saturday, January 20, 2024 - 4:00 AM

CONCLUSIONS: Malignant and benign extracardiac coincidental findings with increased perfusion are readily visible and frequently seen on O-15-H(2)O PET MPI. We recommend evaluating the summed O-15-H(2)O PET images in addition to the low-dose CT

Evaluating the long-term impact of COVID-19-associated public health interventions on zoonotic and vector-borne diseases in China: an interrupted time series analysis

Saturday, January 20, 2024 - 4:00 AM

CONCLUSIONS: China's dynamic zero COVID-19 strategy may have exerted a lasting influence on HFRS, rabies, DF, malaria, and schistosomiasis, beyond immediate consequences, but not affect HB and leptospirosis. ARFIMA emerges as a potent tool for

Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy versus monotherapy for high-risk immunocompromised patients with mild to moderate SARS-CoV2 infection during Omicron era. A prospective cohort study

Saturday, January 20, 2024 - 4:00 AM

CONCLUSIONS: In immunocompromised, combination therapy including sotrovimab plus an antiviral may be more effective than monotherapy for SARS-CoV2.